{"schema_version":"secwatch.filing_event.v1","accession":"0001380106-23-000011","form_type":"8-K","ticker":"RPID","cik":"0001380106","company_name":"RAPID MICRO BIOSYSTEMS, INC.","filed_at":"2023-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.692584+00:00","generated_at":"2026-06-18T12:54:29.961014+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rapid Micro Biosystems Q4 commercial revenue $4.4M, FY2022 $17.1M; guides FY2023 at least $22M","bullets":["Q4 2022 commercial revenue $4.4M (vs $4.9M prior year); net loss $16.4M ($0.39 per share).","Full year 2022 commercial revenue $17.1M (vs $21.6M prior year); net loss $60.8M ($1.43 per share).","Recurring commercial revenue grew 28% in Q4 to $2.9M; full year recurring revenue $11.0M (+40% YoY).","Placed 2 new systems in Q4, 9 in full year; cumulative 125 placed, 103 validated systems.","FY2023 guidance: commercial revenue at least $22M, with at least 15 new system placements."],"urls":{"canonical":"https://secwatch.observer/filing/0001380106-23-000011","json":"https://secwatch.observer/filing/0001380106-23-000011.json","markdown":"https://secwatch.observer/filing/0001380106-23-000011.md","text":"https://secwatch.observer/filing/0001380106-23-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1380106/000138010623000011/0001380106-23-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1380106/000138010623000011/rpid-20230303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T12:54:29.961014+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"01bd723e2a1d281fbc30bab9b3add968b65fd4e3","claim":"RAPID MICRO BIOSYSTEMS, INC. reported the fourth quarter ended December 31, 2022 results: revenue $4.4 million, net income $16.4 million, EPS $0.39.","evidence_excerpt":"Total revenue for the fourth quarter of 2022 was $4.4 million, compared to $5.2 million in the fourth quarter of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1380106/000138010623000011/0001380106-23-000011-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$4.4 million"},{"label":"Net income","value":"$16.4 million"},{"label":"EPS","value":"$0.39"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"b1171dd449f92b68434bbc64e91bf7389b6ea6ea","claim":"RAPID MICRO BIOSYSTEMS, INC. reported the fiscal year ended December 31, 2022 results: revenue $17.1 million, net income $60.8 million, EPS $1.43.","evidence_excerpt":"Total revenue for the full year was $17.1 million in 2022, compared to $23.2 million in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1380106/000138010623000011/0001380106-23-000011-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Revenue","value":"$17.1 million"},{"label":"Net income","value":"$60.8 million"},{"label":"EPS","value":"$1.43"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ece2f1ffd5f3622639a18530c684fa9263963bac","claim":"RAPID MICRO BIOSYSTEMS, INC. reported full year 2023 results: revenue at least $22.0 million. Guidance initiated.","evidence_excerpt":"For the full year 2023, the Company expects commercial revenue of at least $22.0 million, including the placement of at least 15 new systems.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1380106/000138010623000011/0001380106-23-000011-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"at least $22.0 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}